By Nick Sohr – MDBizNews, June 4, 2012
With a technology platform its founder compares to colorful, plastic children’s blocks, Zyngenia is snapping together cutting-edge drugs to combat inflammation and cancer—the first iterations of what could be a long line of innovative products for the Gaithersburg company.
By Kevin McCaffrey – Medical Marketing & Media, June 1, 2012
“The company is a big idea,” says Zyngenia’s new chief business officer, Daniel Menichella. “I believe that Zybodies are the next generation of multi-specific based drugs, particularly in oncology and neurology.” The Maryland-based biotech firm has two preclinical programs in development, which are expected to enter IND in 2013 and 2014.
By Stephen Hansen – BioCentury, March 22, 2010
Combinations of biologics targeting different pathways of a disease have the potential to provide more efficacy than monotherapy, but adding several biologics together is expensive. Zyngenia Inc. believes its Zybody multi-specific antibodies could provide the efficacy of a cocktail of mAbs at a lower cost.
By John Carroll – FierceBiotech, November 5, 2009
A group of MedImmune veterans has joined forces to launch a startup with some new technology out of the Scripps Institute in La Jolla, CA. And they’re concentrating their efforts in their old stomping grounds around Montgomery County, MD.
Washington Business Journal, November 4, 2009
Zyngenia Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million in Series A funding from New Enterprise Associates (NEA), one of the world’s leading venture capital firms.